title: [Hand-foot syndrome with tyrosine kinase inhibitor therapy: treatment recommendations].
abstract: A significant component of advanced renal cell carcinoma therapy is treatment with tyrosine kinase inhibitors. Hand-foot syndrome is a frequent adverse reaction and the quality of life of patients can be considerably affected depending on the severity. Effective treatment options are, therefore, essential and standardization of treatment recommendations is desirable. In this article practical and standardized recommendations for the treatment of outpatients with hand-foot syndrome are introduced and several strategies for prophylaxis and therapy are discussed.
authors.affiliation: Klinik für Dermatologie, Venerologie und Allergologie, Charité-Universtitätsmedizin Berlin, Campus Mitte, Charitéplatz 1, 10117, Berlin, Deutschland, Guido.Burbach@charite.de.
authors.forename: G J
authors.initials: GJ
authors.lastname: Burbach
authors.forename: T
authors.initials: T
authors.lastname: Zuberbier
mesh_terms: D000970:Antineoplastic Agents / Q000009:adverse effects*; D005858:Germany; D060831:Hand-Foot Syndrome / Q000209:etiology* / Q000628:therapy*; D006801:Humans; D017410:Practice Guidelines as Topic; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011505:Protein-Tyrosine Kinases / Q000009:adverse effects* / Q000037:antagonists & inhibitors*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011505:Protein-Tyrosine Kinases